Retrospective analysis of type of KRAS mutation (mut) and response to first-line platinum-based chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts).

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

“…This biological difference may confer greater sensitivity to MEK inhibitors; a hypothesis supported by the results presented here, which highlight how different KRAS mutations may lead to different signal transduction cascades, resulting in altered drug sensitivity. In a recently presented retrospective analysis, patients with KRAS G12V or G12A mutation-positive advanced NSCLC had longer PFS when treated with first-line platinum chemotherapy+taxane compared with those treated with platinum chemotherapy+pemetrexed or gemcitabine, respectively ( Mellema et al , 2014 ). Additionally, in a study of NSCLC cell lines, KRAS G12V mutations were associated with increased sensitivity to cisplatin compared with wild-type KRAS ( Garassino et al , 2011 ).…”